Mark A. Rubin

About Mark A. Rubin

Dr. Rubin and colleagues have identified a unique class of prostate cancer patients that have mutations in the gene for SPOP (Speckle-type POZ Protein). These mutations result in the loss of the critical function of SPOP that leads to increased invasiveness of the tumor cells and metastatic spread of prostate cancer. Dr. Rubin and his team will study in detail the mechanisms by which the SPOP gene is inactivated and the downstream effects of genetic dysregulation at the SPOP level. These findings will help in the design of effective therapeutics for this class of prostate cancer patients. The team will also assess the prevalence of these gene mutations in all patients of prostate cancer. This will help in the overall classification of the disease into distinct classes of patients, with specific therapies directed at each class.
Potential patient benefit: Dr. Rubin’s research will help in the stratification of prostate cancer patients based on genetic subtypes. Discovery of SPOP inhibitors will potentially create a new therapy for metastatic prostate cancer and, in time, will support highly personalized treatment for patients.

Mark A. Rubin, MD –

Weill Cornell Medical College
Recurrent SPOP Mutations in Prostate Cancer: Characterization of a Potentially Targetable Sub-class of Prostate Cancer

Co-investigators:

Pengbo Zhou, PhD; Hao Wu, PhD; Francesca Demichelis, PhD